Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies

Yafeng Ma; Alison Luk; Francis P. Young; David Lynch; Wei Chua; Bavanthi Balakrishnar; Paul de Souza; Therese M. Becker

doi:10.3390/ijms17081264

Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies

Yafeng Ma, Alison Luk, Francis P. Young, David Lynch, Wei Chua, Bavanthi Balakrishnar, Paul de Souza, Therese M. Becker

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs): We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.

Original language	English
Article number	1264
Number of pages	11
Journal	International Journal of Molecular Sciences
Volume	17
Issue number	8
DOIs	https://doi.org/10.3390/ijms17081264
Publication status	Published - 2016

Open Access - Access Right Statement

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

Keywords

androgens
biochemical markers
cancer
prostate
receptors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms17081264

Cite this

@article{b8a978bf949b4990817e24d13d3aca71,

title = "Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies",

abstract = "Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs): We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.",

keywords = "androgens, biochemical markers, cancer, prostate, receptors",

author = "Yafeng Ma and Alison Luk and Young, {Francis P.} and David Lynch and Wei Chua and Bavanthi Balakrishnar and Souza, {Paul de} and Becker, {Therese M.}",

year = "2016",

doi = "10.3390/ijms17081264",

language = "English",

volume = "17",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI AG",

number = "8",

}

TY - JOUR

T1 - Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies

AU - Ma, Yafeng

AU - Luk, Alison

AU - Young, Francis P.

AU - Lynch, David

AU - Chua, Wei

AU - Balakrishnar, Bavanthi

AU - Souza, Paul de

AU - Becker, Therese M.

PY - 2016

Y1 - 2016

N2 - Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs): We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.

AB - Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs): We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.

KW - androgens

KW - biochemical markers

KW - cancer

KW - prostate

KW - receptors

UR - http://hdl.handle.net/1959.7/uws:36620

U2 - 10.3390/ijms17081264

DO - 10.3390/ijms17081264

M3 - Article

SN - 1661-6596

VL - 17

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 8

M1 - 1264

ER -

Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies

Abstract

Open Access - Access Right Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this